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Results: Three hundreds and one patients were enrolled. Nine patients (3%)
were lost to follow-up at one year. The rates of thrombotic and bleeding events
at one year were 7.5 and 6.8% respectively. The mean VASP index after a
60 mg LD of prasugrel was 34}23% and 76 patients (25%) were considered as
having high on-treatment platelet reactivity (HTPR). Patients with HTPR had a
higher rate of thrombotic events compared to good responders (19.7 vs
3.1%;p<0.001). Patients with a minor or major non-CABG related TIMI
bleeding had lower PR compared to patients with no bleeding events (21}18 vs
35}23%;p=0.008). In multivariate analysis, the VASP index predicted both
thrombotic and bleeding events (OR: 1.44 (95% CI: 1.2-1.72; p<0.001 and 0.75
(95% CI: 0.59-0.96;p=0.024 (respectively, per 10% increase)).
Conclusion: Platelet reactivity measurement after prasugrel LD predicts
both ischemic and bleedings events at one year follow-up for ACS patients
undergoing PCI.
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Background: Myocardial bridge (MB) is congenital myocardial band
overriding a portion of a coronary artery, mainly LAD. Incidence on coronary
angiography (CA) appears lesser than on autopsy, which can be ethnics-
related, while clinically all forms of coronary artery disease (CAD) are
reported: from benign arrhytmias up to sudden death.
Aim: We sought to determine incidence of MBs in the Serbian population
along with respective clinical features.
Methods: Retrospective analysis was carried out in the same population,
during the same 1-year time-frame and comprised consecutive: (A) 721 autop-
sies, with LM studies of the tunneled vessel (TV) wall together with the mor-
phometric analysis of the ventricular myocardium supplied by TV
(experimental group) and the ventricular myocardium of the same heart but
with a different blood supply (control group); (B) 4510 CA of symptomatic
patients were re-assessed for presence of MBs.
Results: (A) MBs were described in 6 cases (0.8%): 5 male, all over 70yrs.
Only single MB over LAD were found, while all showed: a) TV' intensive
atherosclerotic changes proximal to MB, only focal in the tunneled part;
b) intensive interstitial fibroses of the TV-supplied myocardium. (B) MBs
were found in 42pts (0.93%): 33 male, aged of 55+11yrs, with single MB over
the mid-LAD. 29% were CAD-free, 43% had 1-vessel CAD, 2-v-CAD (24%)
and 3-v-CAD (4%). MBs were most frequent in hearts with right coronary
dominance (69%). Hypertension and smoking were equally present (69%),
dyslipidemia (59%), family history of CAD (48%) and diabetes (21%). Pts
presented with stable angina (40%), nonspecific symptoms (14%), unstable
angina (7%) and supraventricular arrhythmia (5%), with a history of an ante-
rior wall STEMI vs. NSTEMI in 26% vs. 7%.
Conclusions: This first overview of MBs-incidence in Serbia (0.8% on
autopsy vs. 0.9% on CA) might underestimate its actual presence, which
prompted us to continue prospectively.
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Background: Microalbuminuria and uric acid are emerging as new coronary
risk factors in diabetics and non diabetics, their prevalence as well as their prog-
nostic value in patients with acute coronary syndrome (ACS) are still unclear.
Methods: We propose a prospective study of 175 patients admitted with
ACS with ST segment elevation (mean age of 57, 7±9.6 years (28-89 years),
71% are male, 53% are diabetics, 44% are hypertensive, 12% are followed for
chronic renal failure and 14.7% are overweight. The SCA affected the anterior
territory in 51% of cases. A primary angioplasty was performed in 26% of
cases and a fibrinolysis in 52% of cases.
Results: Microalbuminuria is positive in 22% of cases, affecting 42% of
diabetics and 8.7% of non diabetics, the rate of microalbuminuria is correlated
with the blood sugar level in diabetic and non diabetic (r=0.650, p=0.01 and
r=0.687, p=0.02). 
The uric acid is correlated to the serum creatinine level and the peak of tro-
ponin in patients with a creatinine clearance> 60 ml/mn (r=0.690, P=0.02 and
r=0.740, p=0.001). The uric acid is also correlated to the number of affected
coronary arteries (r=0.602, p=0.02). The rate of microalbuminuria is correlated
to the distribution of atherosclerosis 13±8 mg in single vessel disease vs.
15±7 mg in two vessel disease Vs 29±5 mg in three vessel disease, p=0.02. In
univariate and multivariate analysis, 56% of patients who have microalbumin-
uria presented a three vessel disease vs 23% among other patients, p=0.01,
OR=6.9 (95% ICA 1.7-23) independently of diabetes and hypertension.
Conclusion: The uric acid is not correlated to the diffusion of atheroscle-
rosis after adjustment to diabetes and kidney failure.
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Aim: Even if the recommended duration for dual antiplatelet therapy
(DAT) after non ST elevation acute coronary syndromes (NSTE-ACS) is
12 months, evidence concerning the benefit of clopidogrel adjunction espe-
cially beyond 3 months remains poor. The aim of the study was to assess the
effective clopidogrel intake and the incidence of a composite endpoint
including all causes death and non fatal myocardial infarction in a Tunisian
population after NSTE-ACS.
Methods: We included patients admitted for NSTE-ACS in our depart-
ment between January 2010 and August 2011 for whom long term evalu-
ation was possible. In-hospital deaths were excluded (including post
operative deaths). By telephone follow up, we evaluated the effective DAT
duration and the occurrence of all causes death and non-fatal myocardial
infarction.
Results: One hundred thirty patients were included. Mean (SD) follow up
was 261 (99) days. DAT was effectively observed during 94±103 days
(extremes ranging from 0 to 360 days). Angioplasty was performed in 51.5%,
coronary artery bypass graft in 8.4% and medical therapy was considered in
40.1%. In 35 (26.9%) patients, aspirin was the only antiplatelet therapy taken
after discharge although DAT was prescribed; 46.9% of the patients took the
DAT for more than 3 months, and 23.1% for more than 6 months. The com-
posite endpoint occurred in 6 (4.6%) patients: 2 deaths (both of cardiac
causes) and 4 myocardial infarctions. Three of them were under DAT, and the
3 others remained event free during 7, 240 and 270 days after clopidogrel
withdrawal. These findings suggest that DAT does not protect against death or
myocardial infarction. The rebound phenomenon after clopidogrel withdrawal
isn’t patent in our population.
Conclusion: In the Tunisian context, DAT observance is poor after
NSTE-ACS. Death and non fatal myocardial infarction don’t seem to be
reduced by DAT and the rebound phenomenon after clopidogrel with-
drawal isn’t patent. This may be in part attributed to the small sample of
population and the predominantly low risk (as assessed by TIMI risk
score), but larger studies are needed to strengthen the evidence for DAT
after NSTE-ACS.
